Clinical trial
An 18-month Low-interventional Prospective, Multicentre Study to Assess Joint Outcomes in Patients With Haemophilia A or B on Prophylaxis With Efmoroctocog Alfa or Eftrenonacog Alfa
NCT05856266 is registered in ClinicalTrials.gov with Swedish Orphan Biovitrum as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An 18-month Low-interventional Prospective, Multicentre Study to Assess Joint Outcomes in Patients With Haemophilia A or B on Prophylaxis With Efmoroctocog Alfa or Eftrenonacog Alfa
- Lead sponsor
- Swedish Orphan Biovitrum
- Phase
- Phase 4
- Overall status
- Terminated
- Start date
- August 24, 2023
- Completion date
- December 6, 2023
- Enrollment
- 10 (actual)
- Sites
- 56
Conditions
As the registry lists them; a condition with its own page is linked.